PCSK9 and prostate carcinoma: Similarly, leveraging large-scale summary-level data from PRACTICAL meant that we were unable to evaluate the time-varying effects of PCSK9 inhibition on risk of prostate cancer at separate stages in the life course or in population subgroups undergoing different treatment regimens.